Recent studies have focused on the effects of TGFβ inhibition in stroma-heavy cancers, such as CRC, urothelial carcinoma, and pancreatic ductal adenocarcinoma7,12,18. This evidence concerns the gene TGFB1 and urothelial carcinoma.